A sample report on
Philippines HIV
Therapeutics
Market Analysis
Includes Market Size, Market Segmented by Types
and Key Competitors (Data forecasts from 2022 – 2030F)
www.insights10.com
This report presents a strategic analysis of the Philippines HIV
Therapeutics Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, types of clinical diagnostics, point-of-care testing, main players, growth and demand drivers, challenges & future outlook, etc.
This is one of the most comprehensive reports about the Philippines HIV
Therapeutics Market, and offers unmatched value, accuracy, and expert insights
Report Scope
Report Attribute
Details
Number of Pages
70-80
Base Year for Estimation
2022
Forecast Period
2023-2030
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Report Coverage
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario
Quantitative Units
Revenue in USD Million/Billion (Mn/Bn)
Research Approach
Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 3
Table of Content
CONTENT
PG. NO.
1. HIV Therapeutics Overview
12-25
1.1. Overview
1.2. Philippines Overview
1.3. Economic Overview: Philippines
1.4. HIV Therapeutics Market in Philippines
1.5. Pharmaceuticals Market in Philippines
1.6. Healthcare Scenario in Philippines
1.7. Health Insurance Coverage: Philippines
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting
26-33
2.1 Market size and forecasts (Excel and Methodology)
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 4
Table of Content
CONTENT
PG. NO.
2.2. Market Segmentation
2.2.1 Types
2.2.2. Distribution Channel
3. Market Dynamics
34-38
3.1. Market Growth Drivers
3.1.1. Philippines HIV Therapeutics Market Driver 1
3.1.2. Philippines HIV Therapeutics Market Driver 2
3.1.3. Philippines HIV Therapeutics Market Driver 3
3.2. Market Restraints
3.2.1. Philippines HIV Therapeutics Market Restraint 1
3.2.2. Philippines HIV Therapeutics Market Restraint 2
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 5
Table of Content
CONTENT
PG. NO.
3.2.3. Philippines HIV Therapeutics Market Restraint 3
4. Competitive Landscape
39-49
4.1. Major Market Share
4.2. Key Company Profile
4.2.1. Gilead Sciences
4.2.1.1. Overview
4.2.1.2. Product Applications & Services
4.2.1.3. Recent Developments
4.2.1.4. Partnerships Ecosystem
4.2.1.5. Financials (Based on Availability)
4.2.2. Merck
4.2.2.1. Overview
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 6
Table of Content
CONTENT
PG. NO.
4.2.2.2. Product Applications & Services
4.2.2.3. Recent Developments
4.2.2.4. Partnerships Ecosystem
4.2.2.5. Financials (Based on Availability)
4.2.3. Pfizer
4.2.3.1. Overview
4.2.3.2. Product Applications & Services
4.2.3.3. Recent Developments
4.2.3.4. Partnerships Ecosystem
4.2.3.5. Financials (Based on Availability)
4.2.4. AstraZeneca
4.2.4.1. Overview
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 7
Table of Content
CONTENT
PG. NO.
4.2.4.2. Product Applications & Services
4.2.4.3. Recent Developments
4.2.4.4. Partnerships Ecosystem
4.2.4.5. Financials (Based on Availability)
4.2.5. United Laboratories
4.2.5.1. Overview
4.2.5.2. Product Applications & Services
4.2.5.3. Recent Developments
4.2.5.4. Partnerships Ecosystem
4.2.5.5. Financials (Based on Availability)
4.2.6. Mercury Drug Corporation
4.2.6.1. Overview
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 8
Table of Content
CONTENT
PG. NO.
4.2.6.2. Product Applications & Services
4.2.6.3. Recent Developments
4.2.6.4. Partnerships Ecosystem
4.2.6.5. Financials (Based on Availability)
4.2.7. Novartis
4.2.7.1. Overview
4.2.7.2. Product Applications & Services
4.2.7.3. Recent Developments
4.2.7.4. Partnerships Ecosystem
4.2.7.5. Financials (Based on Availability)
4.2.8. GlaxoSmithKline
4.2.8.1. Overview
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 9
Table of Content
CONTENT
PG. NO.
4.2.8.2. Product Applications & Services
4.2.8.3. Recent Developments
4.2.8.4. Partnerships Ecosystem
4.2.8.5. Financials (Based on Availability)
4.2.9. Johnson & Johnson
4.2.9.1. Overview
4.2.9.2. Product Applications & Services
4.2.9.3. Recent Developments
4.2.9.4. Partnerships Ecosystem
4.2.9.5. Financials (Based on Availability)
4.2.10. ViiV Healthcare
4.2.10.1. Overview
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 10
Table of Content
CONTENT
PG. NO.
4.2.10.2. Product Applications & Services
4.2.10.3. Recent Developments
4.2.10.4. Partnerships Ecosystem
4.2.10.5. Financials (Based on Availability)
5. Reimbursement Scenario
50-57
5.1. Reimbursement Regulation
5.2. Reimbursement Process for Diagnosis
5.3. Reimbursement Process for Treatment
6. Methodology & Scope
58-63
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 11
Philippines HIV Therapeutics Market Analysis
1. HIV Therapeutics Overview
1.1 Statistics at a Glance: The Burden of HIV in the World Prevalence of HIV
▪
Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
38.4 Mn
0.7%
report
are living with HIV
of people aged between 15–
worldwide
49 years worldwide are living
▪
In this section you will get an
with HIV
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
1 in 25
650,000
topic
adults in African
people died of HIV-related
region are affected
illnesses worldwide in 2021
▪
In order to obtain access to all of the
by HIV
information that you are seeking, you will
need to purchase the final report
▪
Final report will be comprehensive and
90
160,000
detailed, and it will include data, analysis,
low- and middle-income
children have acquired
trends, and other relevant information
countries reported a total of 190
HIV in 2021
related to the topic or subject matter of
million people tested and
interest
received results in 2020
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 13
1.1 Statistics at a Glance: The Burden of HIV in the World (continued) Europe
~Revenue to reach
$XX Bn by 2027
North America
~ Market Size of
Asia
$XX Bn
-Fastest CAGR
Africa
~Market Size of
Philippines Market
$XX Bn
~$XX Mn Market
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 14
1.2 Philippines Overview
▪
Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪
In this section you will get an
understanding of the demographics of the
country/region, which includes the
111 Mn
$394 Mn
population, GDP, healthcare expenditure
and other details related to the topic
Is the population of
Is the Gross
Philippines, in 2021
Domestic Product
▪
In order to obtain access to all of the
(GDP) in Philippines
information that you are seeking, you will
in 2021
need to purchase the final report
▪
Final report will be comprehensive and
30
$175
detailed, and it will include data, analysis,
Is the median age
per capita was the
trends, and other relevant information
in Philippines, in
amount of national
related to the topic or subject matter of
2022
health expenditures in
interest
2021
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 15
1.3 Economic Overview: Philippines
Population of Philippines, (2020-2030)
GDP of Philippines, (2020-2030)
XX
XX
XX
XX
2020
2021
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
2020
2021
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population Split (2023)
▪
In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, By Gender
By Age Group
healthcare expenditure and other details related to the topic
▪
In order to obtain access to all of the information that you are 0-14
seeking, you will need to purchase the final report
15-24
Female
Male
▪
Final report will be comprehensive and detailed, and it will 51%
49%
25-54
include data, analysis, trends, and other relevant information 55-64
related to the topic or subject matter of interest
65+
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 16
1.4 Statistics at a Glance: The Burden of HIV in Philippines Prevalence of HIV
▪
Please be aware that this sample report
is intended to provide you with a brief
overview of the kind of information and
21%
41
analysis that will be presented in the
higher cases were
cases of HIV were detected in
final report
detected in 2022
2022 as compared to 34 in
than 2021
2021
▪
In this section you will get an
understanding of the topic, which
includes the prevalence of the disease,
the application of medical devices, new
14,970
4,377
technology, and other details related to
new HIV cases
people diagnosed with
the topic in Philippines
detected between
acquired immunodeficiency
January and
syndrome in 2022
▪
In order to obtain access to all of the
December 2022
information that you are seeking, you
will need to purchase the final report
14,637
95
▪
Final report will be comprehensive and
cases were due to sexual
HIV infections were
detailed, and it will include data,
contact
acquired through sharing
analysis, trends, and other relevant
of infected needles
information related to the topic or
subject matter of interest
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 17
1.5 Pharmaceuticals in Philippines
Philippines Pharmaceuticals Market Forecast, 2022-2030 (in $Bn) XX
2022
2023F
2024F
2025F
2026F
2027F
2028F
2029F
2030F
▪
Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report
▪
In this section you will get an understanding of the overall Pharmaceuticals market in Philippines, which includes the market size, current trends and other details related to the topic
▪
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 18
1.6 Healthcare Scenario in Philippines
HIV Therapeutics Drug Development Process: The process of developing a HIV Therapeutics drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the HIV Therapeutics drug development process: o Preclinical Research: Researchers identify potential drug candidates and test them in the lab o Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans o Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating HIV Therapeutics o Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness
o Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches:
▪
Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat Fast Track
serious conditions and fill an unmet medical need
Breakthrough
▪
A process designed to expedite the development and review of drugs which may demonstrate substantial Therapy
improvement over available therapy
Accelerated
▪
These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved Approval
based on a surrogate endpoint
Priority Review
▪
A Priority Review designation means FDA’s goal is to take action on an application within 6 months Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 19
1.6 Healthcare Scenario: HIV/AIDS Patient Journey
Presentation
Diagnosis
Treatment
Follow up
Confirmatory Diagnosis
Complete blood count
Prevention and management of
(evaluate number &
crisis:
quality of RBCs, Hb &
• For VOC and Splenic
• Long term follow-up is required for
WBCs)
patients with SCD
Initial Diagnosis
Sequestration: HU, Endari,
Adakveo, Oxbryta
• Annual assessment: CBC and
A suspected diagnosis is
Imaging (confirm bone
• For infections: Antibiotics,
reticulocyte count, iron status, liver
usually made, based on
related changes or
Vaccines
and renal function tests, urinalysis,
physical examination and
respiratory problems)
Prenatal screening/
LDH, vitamin D level and
detailed patient and family
Neonatal screening
Bacterial cultures of
neurocognitive assessment
history
blood, sputum, urine,
• ESOD (End Stage Organ Damage)
stool (detect any
Prevention and management of
evaluation starting from age 7
infection)
complications:
• Yearly Transcranial Doppler test to
determine risk of stroke
Genetic testing (detect
• Stroke: Chronic transfusions, HU
the type of SCD)
sr
PCP, pediatrician, neonatologist,
ed
endocrinologist, cardiologist,
l
PCP, paediatrician,
PCP, pediatrician, medical geneticist,
o
neonatologist,
PCP, pediatrician, medical geneticist,
hematologist, orthopedist, psychologist
cardiologist, hematologist,
haematologist and genetic
hematologist, gynecologist and pathologist
and psychiatrist
endocrinologist, psychologist and
counsellor
psychiatrist
Depending on the organ complications,
Stakeh
the treatment involves different
specialists at different times
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 20
1.7 Health Insurance Coverage: Philippines
% of People by Type of Health Insurance Coverage
Number of People By Health Insurance Coverage
(2021)
Coverage Type
2020
2021
Change %
Uninsured
8.3
Total
327,521
328,074
With health insurance
91.7
Any health plan
299,230
300,887
0.4
Any private plan
217,896
216,366
–0.6
Any private plan
66.0
Employment-based
178,737
178,285
–0.2
Employment-based
54.3
Direct-purchase
10.2
Direct-purchase
33,869
33,555
–0.1
Marketplace
3.5
Marketplace coverage
10,924
11,389
0.1
TRICARE
2.5
TRICARE
9,165
8,299
–0.3
Any public plan
112,925
117,095
1.2
Any public plan
35.7
Medicare
58,541
60,226
0.5
Medicare
18.4
Medicaid
58,778
61,940
0.9
Medicaid
18.9
VA and CHAMPVA
2,967
3,151
0.1
VA and CHAMPVA
1.0
Uninsured
28,291
27,187
–0.4
▪
In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year
▪
More people had private health insurance (66%) than public coverage (35.7%)
▪
Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%)
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 21
1.8 Budget of Philippines Government for Public Insurance Proposed Budget By Category
Outlays
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2022-31
Medicare
$769
$709
$766
$841
$840
$947
$1,014
$1,085
$1,227
$1,178
$1,325
$1,412
$10,633
In Billions Of Dollars
Medicaid
$458
$521
$571
$582
$616
$645
$674
$698
$734
$768
$801
$837
$6,926
Medicare
3.7%
3.2%
3.3%
3.4%
3.3%
3.6%
3.7%
3.8%
4.1%
3.8%
4.1%
4.2%
3.7%
As % Of GDP
Medicaid
2.2%
2.4%
2.4%
2.4%
2.4%
2.4%
2.4%
2.4%
2.5%
2.5%
2.5%
2.5%
2.4%
▪
National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪
Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪
Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪
Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪
Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪
Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪
Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪
Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪
Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪
Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 22
1.9 Mergers and Acquisitions
RCM M&A Deal Value Trend ($Bn)
RCM M&A Deal Volume Trend
$16.7
112
107
107
110
89
$11.7
82
$10.5
$7.7
$6.8
$6.0
1H 2020
2H 2020
1H 2021
2H 2021
1H 2022
2H 2022
1H 2020
2H 2020
1H 2021
2H 2021
1H 2022
2H 2022
Buyer Composition: Strategic Vs Financial (2020)
Buyer Type by Deal Size
41%
41%
42%
39%
($Mn)
59%
59%
58%
61%
Strategic Buyers
Financial Buyers
$0- $25
$25-$50
$50-$100
$100+
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 23
1.9 Mergers and Acquisitions (continued)
Latest Deals In Philippines
Amount /
Company Name
Type
Year
Key Pointers
Duration
▪
Oracle’s acquisition of Cerner is big tech’s latest foray into the healthcare system, promising better outcomes
▪
Oracle acquire Cerner through an all-cash tender offer for $95.00
per share, or approximately $28.3 Bn in equity value
Acquisition
$28.3 Bn
June, 2022
▪
Cerner is a leading provider of digital information systems used within hospitals and health systems to enable medical
Oracle acquisition of
professionals to deliver better healthcare to individual patients Cerner
and communities
▪
GSK has acquire BELLUS for US$14.75 per share of common
stock in cash representing an approximate total equity value of US$2.0 billion
▪
BELLUS is a late-stage biopharmaceutical company working to Acquisition
$2 Bn
April 2023
better the lives of patients suffering from persistent cough
▪
Acquisition further strengthens specialty medicines and
respiratory pipeline with camlipixant, a highly selective P2X3
GSK acquisition of
antagonist and potential best-in-class treatment for refractory BELLUS Health
chronic cough
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 24
1.9 Mergers and Acquisitions (continued)
Latest Deals In Philippines
Amount /
Company Name
Type
Year
Key Pointers
Duration
Merger
March 2023
Merger
Jan 2023
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 25
Philippines HIV Therapeutics Market Analysis
2. Market Size and Forecasting
2.1 Market size and forecasts (Excel and Methodology)
Click on the icon to know the
Philippines HIV Therapeutics Market Forecast, 2022-2030 (in $Bn) methodology and assumption
▪
Please be aware that this sample report
XX
is intended to provide you with a brief
XX
overview of the kind of information and
analysis that will be presented in the
final report
▪
In this section you will get an
understanding of the overall Healthcare
Insurance market in Malaysia, which
includes the market size, current trends
2022
2023F
2024F
2025F
2026F
2027F
2028F
2029F
2030F
and other details related to the topic
2023
2024
2025
2026
2027
2028
2029
2030
▪
In order to obtain access to all of the
Major Markets Patient
2.74
2.82
2.90
2.94
2.98
3.02
3.07
3.12
information that you are seeking, you
(Mn)
will need to purchase the final report
Philippines Patient Size
0.51
0.61
0.68
0.69
0.70
0.71
0.72
0.73
▪
Final report will be comprehensive and
(Bn)
detailed, and it will include data,
% of US Patients
18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
analysis, trends, and other relevant
information related to the topic or
Global Market Size (Bn $)
3,620
3,780
3,950
4,128
4,314
4,508
4,711
4,937
subject matter of interest
Philippines Market Size
61
74
84
87
91
95
99
106
(Bn $)
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 27
2.2 Snapshot of HIV Therapeutics Market Segmentation
Types
Distribution Channel
Nucleoside-Analog Reverse
Hospital Pharmacies
Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Retail Pharmacies
Entry and Fusion Inhibitors
Online Pharmacies
Integrase Inhibitors
Others
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase
Inhibitors (NNRTIs)
▪
In this section you will get an understanding of the segmentations which will cover the Philippines HIV Therapeutics Market
▪
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 28
2.2.1 Market Segmentation: By Types
▪
Nucleoside-Analog Reverse
Transcriptase Inhibitors market in
Philippines HIV Therapeutics Market Share, By Types (2022) Philippines is a significant component
of the overall HIV therapeutics
treatment market
Non-Nucleoside
Protease
Reverse
▪
It has the maximum market share in
Inhibitors (PIs)
Transcriptase …
Philippines HIV therapeutics market
with approximately xx%
▪
Please be aware that this sample report
Nucleoside-
Integrase
is intended to provide you with a brief
Analog Reverse
Inhibitors
overview of the kind of information and
Transcriptase
Inhibitors (NRTIs)
analysis that will be presented in the
final report
▪
In order to obtain access to all of the
information that you are seeking, you
Entry and Fusion
will need to purchase the final report
Inhibitors
▪
Final report will be comprehensive and
detailed, and it will include data,
analysis, trends, and other relevant
Coreceptor
information related to the topic or
Antagonists
subject matter of interest
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 29
2.2.2 Market Segmentation: By Distribution Channel
▪
Hospital Pharmacies market in
Philippines is a significant component
Philippines HIV Therapeutics Market Share, By Distribution of the overall HIV therapeutics market
Channel (2022)
▪
It has the maximum market share in
Others
Philippines HIV therapeutics market
with approximately xx%
▪
Please be aware that this sample report
is intended to provide you with a brief
Hospital
overview of the kind of information and
Pharmacies
analysis that will be presented in the
Online
final report
Pharmacies
▪
In order to obtain access to all of the
information that you are seeking, you
will need to purchase the final report
▪
Final report will be comprehensive and
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
Retail
Pharmacies
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 30
Philippines HIV Therapeutics Market Analysis
3. Market Dynamics
3.1 Market growth drivers
3.1.1 Incidence of HIV Therapeutics is increasing in Philippines, with more than 1.8 Mn new HIV Therapeutics cases expected to be diagnosed in 2023
▪
Incidence of HIV Therapeutics is increasing in Philippines, with more than Incidence of HIV Therapeutics in
1.8 Mn new HIV Therapeutics cases expected to be diagnosed in 2023
Philippines
▪
This is driving the demand for HIV Therapeutics treatments and creating opportunities for growth in the HIV Therapeutics market
▪
Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report
▪
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest
2010
2022
2030
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 32
3.1 Market growth drivers (continued)
3.1.2 Death rate from HIV Therapeutics in Philippines has declined by 31% from 1992 to 2022, largely due to advances in technology and treatment options
Top countries that are leveraging
▪
Philippines has a long history of investing in HIV
technology in their fight against HIV
Therapeutics research and treatment, and as a result, has Therapeutics
become a world leader in the field
Norway
▪
IT has a robust healthcare infrastructure, including world-Austria
Denmark
renowned research institutions, hospitals, and clinics, that Belgium
are dedicated to HIV Therapeutics treatment and research
Spain
Italy
▪
One of the key factors that has allowed Philippines to stay Netherlands
ahead in the field of HIV Therapeutics research and
Sweden
treatment is the high level of investment in HIV
Singapore
Therapeutics-related research
Switzerland
Israel
▪
In order to obtain access to all of the information that you are Australia
seeking, you will need to purchase the final report
Canada
France
▪
Final report will be comprehensive and detailed, and it will United Kingdom
include data, analysis, trends, and other relevant information China
related to the topic or subject matter of interest
South Korea
Germany
Japan
United States
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 33
3.1 Market growth drivers (continued)
3.1.3 In 2021, the National HIV Therapeutics Institute (NCI) received $6.4 Bn in funding from Philippines federal government to support HIV Therapeutics research and training programs
▪
Philippines government provides significant support and
Fundings from government and other
funding for HIV Therapeutics research and treatment, which organizations
is driving innovation and growth in the HIV Therapeutics
market
Source
Year
Fund ($)
▪
Please be aware that this sample report is intended to
National HIV
provide you with a brief overview of the kind of information Therapeutics
2021
$ 6.4 Bn
and analysis that will be presented in the final report
Institute (NCI)
▪
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Centers for Disease
Control and
2021
$ 501 Mn
▪
Final report will be comprehensive and detailed, and it will Prevention (CDC)
include data, analysis, trends, and other relevant information related to the topic or subject matter of interest
American HIV
Therapeutics Society
2020
$ 150 Mn
(ACS)
Susan G. Komen
2020
$ 98 Mn
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 34
3.2 Market restraints
3.2.1 In 2020, the
3.2.2 Average cost of
3.2.3 Demand for HIV
average cost of a new
developing a new HIV
Therapeutics care is expected to
HIV Therapeutics drug
Therapeutics drug that is
increase by 42% by 2025, while
was over $150,000 per
ultimately approved by the
the supply of oncologists is only
year
FDA is over $2.6 Bn
expected to increase by 28%
▪
HIV Therapeutics treatments can
▪
Regulatory requirements for HIV
▪
There is a shortage of
be very expensive and can lead
Therapeutics treatments can be
oncologists in Philippines, which
to financial burden for patients
very stringent, which can slow
can limit access to HIV
and healthcare systems
down the approval process and
Therapeutics treatments and
▪
Cost of HIV Therapeutics
limit access to new treatments
create barriers to growth in the
treatment varies depending on
▪
Regulatory bodies, such as
HIV Therapeutics market
the type of HIV Therapeutics,
Philippines Food and Drug
▪
Oncologists are physicians who
stage of HIV Therapeutics, and
Administration (FDA), require
specialize in the diagnosis and
treatment options
extensive clinical trials and
treatment of HIV Therapeutics
▪
Some common HIV Therapeutics
safety data before approving
▪
With the aging population and
treatments, such as
new HIV Therapeutics
the increasing incidence of HIV
chemotherapy and radiation
treatments
Therapeutics, there is a growing
therapy, can cost tens of
▪
This can be a lengthy and costly
demand for oncologists
thousands of dollars
process, which can delay the
▪
However, the supply of
availability of new treatments for
oncologists is not keeping pace
patients
Our analysis will thoroughly investigate the key restraints that may significantly impact business
with the demand
operations and growth.
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 35
Philippines HIV Therapeutics Market Analysis
4. Competitive Landscape
4.1 Major Market Share
Revenue of Major players in Philippines HIV
▪
Philippines HIV Therapeutics market is a
Therapeutics Market ($ Mn)
highly competitive space, with many
companies developing and marketing HIV
Other
Therapeutics treatments
▪
Some of the top companies in Philippines
HIV Therapeutics market based on
revenue and market share include
▪
In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪
Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
XX
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 37
4.2 Key Company Profile
Key Note:
1
Gilead Sciences
▪
Here is the list of top 10 companies which
will cover in the final report
2
Merck
▪
Each company will have slides for
o Overview
3
Pfizer
o Key details
4
AstraZeneca
o Offerings
o Name of products
5
United Laboratories
o Recent activities/ Press Coverage
Mercury Drug
o Distribution and Vendor Partners
6
Corporation
o Mergers, Acquisitions and
Collaboration
7
Novartis
o Financials
8
GlaxoSmithKline
▪
If there are specific companies that you
would like to be included in the report,
please let us know via email
9
Johnson & Johnson
▪
In order to obtain access to all of the
information that you are seeking, you will
ViiV Healthcare
10
need to purchase the final report
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 38
4.2.1 Gilead Sciences
Solutions offered by Gilead
Founded in: 1987
▪ Gilead Sciences is a biopharmaceutical business that conducts research to find, develop, and market novel medications in areas
➢ Therapeutic Areas
HQ: California, US
where there is an unmet medical need
▪
➢ Medicines
It focuses on the discovery and development of antiviral medicines Type: Private
for the treatment of HIV/AIDS
➢ Pipeline
▪ Gilead is pushing innovation that has the potential to become the Revenue: $24.6 Mn
next generation of life-changing medications via bold and
➢ Research
revolutionary research
Website: www.gilead.com
➢ Clinical Trials
Drugs for HIV
Recent Activity / Press Coverage
Therapeutics
Drugs
Indications
With the acquisition of XinThera, Gilead strengthens its early pipeline in Biktarvy®
Patients weighing atleast 14 Kg
oncology and inflammation
Complera®
Patients in 12 years and above
CHMP Issues Positive Opinion Recommending Hepcludex® (Bulevirtide) for Descovy®
Patients weighing atleast 35 Kg
Full Marketing Authorization for Hepatitis Delta Virus (HDV) Treatment Emtriva®
HIV-1 infection
Genvoya®
Patients weighing atleast 25 Kg
Gilead continues to work to stop the distribution of counterfeit HIV
medications and ensure patient safety
Odefsey®
Patients in 12 years and above
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 39
4.2.1 Gilead Sciences (continued)
Partnerships Ecosystem
Gilead HIV Age Positively initiative aims to enhance care, offer education, and shape policy for the expanding number of people living with HIV and aging
Scholarship provides financing to organizations that serve Black populations affected by triple-negative breast cancer (TNBC) Toward Health Equity Oncology Grant™ (THE Oncology Grant) is an annual effort that catalyzes new methods to improving health equality across the cancer treatment continuum
RADIAN is an innovative collaboration between Gilead Sciences and the Elton John AIDS Foundation to address new HIV
infections and deaths from HIV-related diseases in Eastern Europe and Central Asia, with the goal of improving the quality of prevention and care for persons at risk of or living with HIV
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 40
4.2.1 Gilead Sciences (continued)
Latest Deals - Mergers and Acquisitions
Amount /
Company Name
Type
Year
Key Pointers
Duration
▪
This Acquisition expands Gilead's existing clinical development goals by adding pipeline assets for well-validated cancer and inflammatory areas
Acquisition
-
May 2023
▪
Xinthera
Gilead acquires access to a portfolio of small molecule inhibitors targeting PARP1 in cancer and MK2 in inflammatory illnesses, which might enter clinical trials later this year
▪
MiroBio's patented discovery methodology and comprehensive range of immune inhibitory receptor agonists are now available to Gilead
September
Acquisition
$405 Mn
2022
▪
MB272, MiroBio's primary investigational antibody, is a selective MiroBio
agonist of the immunological suppressive receptors B- and T-Lymphocyte Attenuator (BTLA) that has begun Phase 1 clinical trials
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 41
4.2.1 Gilead Sciences (continued)
Revenues ($Bn), 2020-2030
▪
According to Gilead's 2020 financial report,
the company had sales of CHF 58.3 Bn
(Swiss Francs) in 2020
▪
This is equivalent to approximately $63.3
Bn USD, based on exchange rates at the
XX
end of 2020
▪
Company's Pharmaceuticals Division
generated sales of CHF 49.9 Bn in 2020,
2020
2021
2022
2023F
2024F
2025F
2026F
2027F
2028F
2029F
2030F
while the Diagnostics Division generated
sales of CHF 8.4 Bn
Breakdown of Net Revenue by Segment, 2022
▪
Revenue generated by Gilead in 2020
reflects the company's continued growth
and success in the healthcare industry
▪
In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
1
2
3
4
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 42
4.2.2 Company 2
Solutions offered by Company
Founded in:
HQ:
Type:
Revenue:
Website:
Drugs for HIV
Recent Activity / Press Coverage
Therapeutics
Drugs
Indications
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 43
4.2.2 Company 2 (continued)
Partnerships Ecosystem
Major Distribution Partners
Major Vendor Partners
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 44
4.2.2 Company 2 (continued)
Latest Deals - Mergers and Acquisitions
Amount /
Company Name
Type
Year
Key Pointers
Duration
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 45
4.2.2 Company 2 (continued)
Revenues ($Bn), 2020-2030
▪
Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
xx
xx
xx
report
▪
In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
2020
2021
2022
2023F
2024F
2025F
2026F
2027F
2028F
2029F
2030F
availability
▪
In order to obtain access to all of the
Breakdown of Net Revenue by Segment, 2022
information that you are seeking, you will
need to purchase the final report
▪
Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
1
2
3
4
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 46
Philippines HIV Therapeutics Market Analysis
5. Reimbursement Scenario
5.1 Reimbursement Regulation
Medicare and Medicaid together provide
The reimbursement scenario in the US HIV Therapeutics market is complex and health insurance coverage for more than
can vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider:
4 in 10 Americans
▪
Medicare:
o Medicare is a federal health insurance program for people aged 65 and Other Public
older, as well as people with certain disabilities or health conditions 1%
o Medicare covers many HIV Therapeutics treatments, including Other Private
chemotherapy, radiation therapy, and some immunotherapies 3%
Uninsured
o
9%
However, coverage can be subject to strict guidelines and restrictions, Medicare
17%
such as the requirement for prior authorization
▪
Medicaid:
o Medicaid is a joint federal-state program that provides health insurance for people with low incomes
o Medicaid coverage for HIV Therapeutics treatments can vary by state, Medicaid
and CHIP
and may be subject to limits on the amount and type of treatment 21%
covered
▪
Private Insurance:
o Private insurance coverage for HIV Therapeutics treatments can also Employer-Sponsored
49%
vary widely depending on the insurer and the specific policy o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage Health Insurance Coverage, 2022
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 48
5.1 Reimbursement Regulation (continued)
▪
Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to HIV Therapeutics treatments by requiring insurers to cover certain preventive services, including HIV Therapeutics screenings, without co-pays or deductibles o It also includes protections for people with pre-existing conditions, such as HIV Therapeutics
▪
Reimbursement for New Treatments:
o Reimbursement for new HIV Therapeutics treatments can be a complex and lengthy process, as insurers and government programs often require evidence of safety and effectiveness before providing coverage o This can create challenges for companies developing and marketing new treatments
▪
Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the value of treatments rather than simply the volume of treatments o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 49
5.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population)
Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
100%
100%
100%
100%
100%
0%
Government Expenditure
0%
xx
xx
xx
xx
xx
7%
%
Public Healthcare
44.
0
8%
46.
.
47.
15
51.
Private Health Insurance
Coverage
Out of Pocket
Private Coverage
9%
1%
6%
5%
5%
38.
37.
35.
32.
31.
Other
NA
NA
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Public healthcare coverage is provided by the government and includes programs like Medicare and Medicaid
6.3%
4.08%
5.1%
3.8%
2.2%
2.4%
3.6%
GDP Growth (yoy)
Medicare is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities 14.7%
11.3%
15.5%
7.5%
4.2%
NA
NA
HC Spend Growth (yoy)
Medicaid is a joint federal-state program that provides healthcare coverage to individuals with low income and limited resources
Reimbursement Market Trends
▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 50
5.2 Reimbursement Process for Diagnosis of HIV Therapeutics The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪
Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪
Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided
▪
Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud
▪
Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule
▪
Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost of the service, such as deductibles, co-payments, or co-insurance In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 51
5.3 Reimbursement Process for Treatment of HIV Therapeutics The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare FDA
provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪
Service or Treatment Provided: The healthcare provider performs a Market Authorization
service or treatment for the patient
▪
Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service Private Payers
Public Payers
provided
▪
Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment Health Technology Assessment
provided, and checking for any potential errors or fraud
▪
Payment: If the claim is approved, the insurance company or other 1
2
3
payer reimburses the healthcare provider for the service provided, Coding
Coverage
Payment
based on the negotiated payment rates or fee schedule
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 52
5.4 Reimbursement Process - Medicare
Medicare
▪ 100% population is covered under this scheme
Population Covered
▪ Citizen’s contribute to this scheme which then earns an interest. There is Basic Healthcare Sum (BHS) cap which limits the maximum contribution to an individuals Medicare account
Provider Restrictions/
Services can be claimed from Medicare-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community Selection
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits Services Covered
▪ Patients above 65 years of age can claim under Flexi-Medicare and further reduce their out-of-pocket expenses by using up to $200 per patient per year from their Medicare account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicare account; Drugs used for cosmetic purposes such as slimming pills and hair loss pills cannot be claimed from this account
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicare up to $500 per account per year, however a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures Level of Coverage/ Assurance
▪ Outpatient scans/ diagnostics for HIV Therapeutics up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
▪ DRG with Activity Based Funding for public providers
Mechanism of Coverage
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility
▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 53
5.5 Reimbursement Process - Medicaid
Medicaid
▪ 38% population is covered under this scheme
Population Covered
▪ Medicare covers individuals who are aged 65 and older, as well as those with certain disabilities or end-stage renal disease Provider Restrictions/
Services can be claimed from Medicaid-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community Selection
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits Services Covered
▪ Patients above 65 years of age can claim under Flexi-Medicaid and further reduce their out-of-pocket expenses by using up to $200 per patient per year from their Medicaid account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicaid account; Drugs used for cosmetic purposes such as slimming pills and hair loss pills cannot be claimed from this account
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicaid up to $500 per account per year, however a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures Level of Coverage/ Assurance
▪ Outpatient scans/ diagnostics for HIV Therapeutics up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
▪ DRG with Activity Based Funding for public providers
Mechanism of Coverage
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility
▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account Illustrative
A Sample Report on Philippines HIV Therapeutics Market Analysis I Confidential 54
Philippines HIV Therapeutics Market Analysis
6. Methodology & Scope
▪
Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive overview of the competitive landscape to help our clients make informed strategic decisions
▪
We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government and regulatory published material, technical journals, trade magazines, and paid data sources
▪
For forecasting, the following parameters are considered:
❑
Market drivers and restraints along with their current and expected impacts
❑
Technological scenario and expected developments
❑
End use industry trends and dynamics
❑
Trends in the consumer behavior
❑
Regulatory scenario and expected developments
❑
Current capacity and expected capacity additions up to 2030
▪
We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected market growth rate
▪
We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-sensitive, reflecting the most recent value and volume of the market across regions
▪
All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪
Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)
Analysis Methodology
Our Analysis Methodology involves three critical stages:
Data
Market Data Analysis
Interpretation &
Collection
& Statistical Model
Presentation
Secondary
Analysis &
Market Trends
Research
Interpretation
Primary
Market Sizing &
Insights
Research
Analysis
Proprietary
Data Triangulation &
Presentation &
Database
Validation
Reporting
Data Triangulation & Data Validation
Top Down Approach
Final
Final Market size break up to
Market
rest of segmentation
Size
Validation from
Arriving at market size
Primary Interview
of each segment
Summarization of revenue
generated from companies
Validation from
to arrive at total market size
Primary Interview
Revenue generated by products &
Final
services offered by companies
Summary
Bottom Up Approach
Key Benefits for Stakeholders from this Report Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided Comprehensive quantitative analysis of the industry from 2022 to 2030F is provided to enable the stakeholders to capitalize on the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors
Time Frame
Report Attribute
Details
Quantitative Units
Revenue in USD Million/Billion (Mn/Bn)
Base Year for
2022
Estimation
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Report Coverage
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (3 to 5 working days)
with purchase. We will provide you with data
Customized Report
that is currently not a part of our scope as a
2023-
Forecast
part of customization
2030
Period
Pricing and purchase
Avail customized purchase options to meet
options
your exact research needs
A division of
Lifesciences Market
Research Reports you
can trust
Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
Get actionable insights to
take informed business
decisions
A large database of over 30,000 syndicated
market research reports in Pharmaceuticals and
healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Elevate your business plans
with in-depth market analysis
and industry intelligence
Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life sciences market
Gain a competitive edge with
Insights10's customized
healthcare research solutions
Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Market Research Reports
across various categories
Pharmaceuticals
Digital
Medical
Healthcare
OTC &
Clinical
(Diseases & Drugs)
Health
Devices
Services
Nutraceuticals
Trials
FEATURED REPORTS
FREE SAMPLE REPORTS
TRENDING TOPICS
What makes us different?
30000+
22000+
2000+
1200+
Life science
Country
Rare & orphan
Reports
Market Research
Specific
Disease
Published
Reports
Reports
Reports
Annually
Table of Contents
Market Overview
Competitive Landscape
1
6
Growth Drivers &
Key Company Profiles
2
7
Growth Restraints
Epidemiology &
Policy & Regulatory
3
8
Disease type
Landscape
insights on
which our
reports are
Market Segmentation
based
4
9
Reimbursement Scenario
Market Share
5
10
Factors Driving Future Growth
Our Services
Market Research
Customized
Primary
Reports
Reports
Research
Database
Full-Time
Conference
Service
Engagement
Coverage
Competitive
Regulatory
Subscription
Intelligence
Compliance
Over the years, we have developed an in-depth experience of executing market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions
Research Projects Done
Our Research Process
01
02
03
04
05
Identification of
Market
Collection of
Collaboration
Verification &
Data
Dynamics
Data
of Data
Analysis
Statistical Databases
Company Websites/Annual Reports
Data
Sources
Trade Publications
We have access to multiple highly
Online Databases
reliable free and subscription data
sources. We have many years of
experience to understand which
Published Research Reports
sources are more dependable for what
and which to prefer for the reliable and
Whitepapers
latest information.
Press Releases of Key Market Players
What kind of data is presented
in our reports?
Our reports present data, which is:
Reliable
Expert-verified
Real
Comprehensive
Easy to read
The report is
The data is prepared
Allowing you to
Covers everything
You do not have to
prepared using a
by a team of highly
confidently make
you would need to
be a market expert
proven methodology
qualified &
smarter business
know about the
to understand what
and insightful
experienced research
and strategic
market including
really is happening
research
analysts & vetted by
decisions
market size,
on the market and
our local associates
competitive analysis
how it works
& much more
The team
“The business decision-making process is no longer as straightforward as it used to be. It requires insights generated at the right time, based on reliable data
interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market
research and are committed to providing our clients with the right intelligence and insights to make business
decisions quickly and efficiently.
Insighs10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working with some of the best organizations in the world,
generating insights that provides substantial competitive advantage.”
Dr. Purav Gandhi
Founder & CEO
Leadership Team
Dr. Purav Gandhi
Anish Swaminathan
Mukesh Nayak
Ritu Baliya
Founder & CEO
Director
Head – Marketing & Research
Engagement Manager
Purav is a physician and an entrepreneur
Anish has 15+ years of experience
Mukesh is an engineering graduate with
Ritu has over 6 years of experience in
with 12+ years of experience in Healthcare
in management consulting in the
an MBA in Marketing. He is a seasoned
strategy building, market assessments,
& Life Sciences industry spanning across
Life Sciences sector, and has
healthcare market research & marketing
market sizing, and RWE for global MNC
strategy, market access, health informatics
worked with diverse multinational
professional with a progressive
healthcare & biopharma clients across diff.
and RWE, digital health, analytics and data
firms in the US, India, Middle East
experience of over 20 years in Life
markets (America, Europe, Africa, APAC
science. Purav studied medicine from
and APAC regions. His primary
Sciences, Pharma and Medical Device
and Middle East). Her areas of expertise
Gujarat University and also completed his
area of interest is Customer and
sectors. With an in-depth understanding
include: Indentifying emerging trends in life
MBA from IIM-Kozhikode. Purav started
Market Strategy, Market Access,
of primary research, he has conducted
sciences industry, Competitor landscape
his career with Deloitte working on strategy
and Digital Health with special
hundreds of interviews of various
assessment, Disease opportunity
consulting engagements and also co-
focus on emerging markets like
stakeholders in pharma & healthcare &
assessments etc. She is a pro in secondary
founded ConvergeHealth by Deloitte.
Africa, Middle East and APAC.
completed several research projects
and primary research with a deep domain
across life sciences industry.
expertise in healthcare sector.
Our Team
Our Clients
Our Clients
… and many more
Do you have
any questions?
We would be happy to help.
Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
Thank you
We truly appreciate your business and
look forward to serving you.
www.insights10.com
